Redhill Biopharma Ltd.
RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill is currently pursuing three Phase III GI programs in the U.S., for Crohn’s disease, H. pylori infection and acute gastroenteritis, and is also pursuing promotion activities in the U.S. with the GI drug Donnatal®
DDW Tracks Microbiome in Gastrointestinal and Liver Diseases, Inflammatory Bowel Diseases, Liver Diseases and Transplantation, Esophageal Diseases, Stomach and Small Bowel Disorders, Colorectal Diseases, Functional GI and Motility Disorders, Pancreatic Diseases, Biliary Tract Diseases
Does your company only service US attendees? No
Is your company a new exhibiting company? Yes